RedHill Biopharma Ltd.RDHLNASDAQ
Loading
| Metric | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -28.40% | +382.03% | +382.03% | +58.59% | +58.59% |
| Gross Profit Growth | -41.01% | +3818.09% | +3818.09% | +111.64% | +111.64% |
| EBITDA Growth | -249.42% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | -302.89% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | -133.33% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | -133.33% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +645.85% | +370.14% | +230.00% | -23.34% | -23.34% |
| Weighted Average Shares Diluted Growth | +645.85% | +370.14% | +230.00% | -23.34% | -23.34% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -34.77% | -2.01% | +37.63% | +449.28% | +63.79% |
| Inventory Growth | -22.98% | -16.81% | -16.81% | -16.69% | -16.69% |
| Asset Growth | -37.14% | -21.71% | -21.71% | -16.57% | -16.57% |
| Book Value per Share Growth | -99.76% | +0.00% | +0.00% | +0.00% | +0.00% |
| Debt Growth | -75.57% | -69.65% | -69.65% | -61.65% | -61.65% |
| R&D Expense Growth | -73.58% | -22.39% | -22.39% | +46.28% | +46.28% |
| SG&A Expenses Growth | -44.44% | -45.37% | -45.37% | -34.29% | -34.29% |